Plasma symmetric dimethylarginine as a metabolite biomarker of severe acute ischemic stroke
In a large clinical cohort of stroke patients with moderate to severe symptoms, our data suggest that SDMA can assist in differentiation of IS and HS patients already 1 h and a half after symptom onset. SDMA may prove to have future value in a diagnostic stroke biomarker panel.
Authors
- Juhani Ritvonen
- Gerli Sibolt (ORCID: https://orcid.org/0000-0003-4815-073X)
- Heini Harve‐Rytsälä (ORCID: https://orcid.org/0000-0002-0104-4553)
- Daniel Strbian (ORCID: https://orcid.org/0000-0001-9095-2344)
- Olli S. Mattila
- Mikko Pystynen
- Sami Curtze (ORCID: https://orcid.org/0000-0003-1545-8500)
- Tiina Nukarinen
- Markku Kuisma (ORCID: https://orcid.org/0000-0002-3057-6524)
- Saana Pihlasviita
- Perttu J. Lindsberg (ORCID: https://orcid.org/0000-0001-7690-811X)
- Turgut Tatlisumak (ORCID: https://orcid.org/0000-0002-2430-8988)
Institutions
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
- Sahlgrenska University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2024-11-07
- DOI
- https://doi.org/10.3389/fneur.2024.1472424
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Suomen Lääketieteen Säätiö
- Biomedicum Helsinki-säätiö
- Jane ja Aatos Erkon Säätiö
- Sigrid Juséliuksen Säätiö